On March 12, 2024, Oramed Pharmaceuticals Inc. appointed Mr. Yehuda Reznick to serve as a director, effective as of April 1, 2024, to fill an existing vacancy on the board of directors (the "Board"). Mr. Reznick was also appointed to serve as a member and chair of the audit committee of the Board, and Mr. Reznick was designated as the audit committee "financial expert". Yehuda Reznick, age 76, served as an audit partner at Kesselman & Kesselman CPA, a member of PricewaterhouseCoopers International Limited, from 1999 until 2014.

Prior to joining Kesselman & Kesselman, he was a tax and audit partner at Shachak, Peer Reznick CPA for sixteen years. Mr. Reznick currently serves on the board of directors of Oravax Medical Inc., an affiliate of the Company. Since 2019, Mr. Reznick has also served on the board of directors of Hiron-Trade Investments & Industrial Buildings Ltd. Mr. Reznick previously served on the board of directors of Bonus Biogroup Ltd. from 2017 to 2023.

As remuneration for his service as a director, Mr. Reznick will receive the same fees as the Company's other non-executive directors.